About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Spectro-IRM and Evaluation Response to Prostatic Radiotherapy

NCT01412853·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Centre Georges Francois Leclerc

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

1. Patients with a biopsy-proven prostatic adenocarcinoma
2. Gleason score between 4 and 10
3. Maximal baseline PSA \< 50 ng/ml
4. Age over or = to 18 yr
5. Exclusive radiotherapy and/or brachytherapy with or without androgen deprivation therapy
6. Written informed consent from the patient

You may not be if

1. lymph-node metastases
2. Bone metastases
3. Maximal baseline PSA ≥ 50 ng/ml
4. Prior radical prostatectomy
5. Contra-indications for MRI (Pace-maker, hip prothesis…)

The record

StatusCompleted

PhaseNo phase

Taking part90

StartedFeb 2008

UpdatedJun 21, 2017

Conditions

Prostate Cancer

Where1

Centre Georges François Leclerc
Dijon, France

Clareo Health | Spectro-IRM and Evaluation Response to Prostatic Radiotherapy